PCNX1

Summary

PCNX1 (pecanex 1, HGNC:19740) is a protein-coding gene on chromosome 14q24.2, encoding Pecanex-like protein 1 (Q96RV3).

This gene encodes an evolutionarily conserved transmembrane protein similar to the pecanex protein in Drosophila. The fly protein is a component of the Notch signaling pathway, which functions in several developmental processes.

Source: NCBI Gene 22990 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 78 total
• MANE Select transcript: NM_014982

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19740
Approved symbol	PCNX1
Name	pecanex 1
Location	14q24.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0995, KIAA0805, pecanex
Ensembl gene	ENSG00000100731
Ensembl biotype	protein_coding
OMIM	617655
Entrez	22990

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 6 protein_coding_CDS_not_defined, 5 protein_coding, 4 retained_intron

ENST00000304743, ENST00000439984, ENST00000553272, ENST00000553428, ENST00000553508, ENST00000554292, ENST00000554691, ENST00000554707, ENST00000554879, ENST00000555780, ENST00000556272, ENST00000556516, ENST00000556846, ENST00000556849, ENST00000557428

RefSeq mRNA: 2 — MANE Select: NM_014982 NM_001308160, NM_014982

CCDS: CCDS76695, CCDS9806

Canonical transcript exons

ENST00000304743 — 36 exons

Exon	Start	End
ENSE00001136831	70995741	70995925
ENSE00001592104	71028700	71028791
ENSE00001597007	71019009	71019162
ENSE00001621812	71036065	71036157
ENSE00001648441	71026772	71026882
ENSE00001649294	71045133	71045283
ENSE00001680179	71023200	71023232
ENSE00001684671	71047807	71047984
ENSE00001686239	71033429	71033538
ENSE00001696589	71046964	71047105
ENSE00001707679	71011492	71011549
ENSE00001714212	71073545	71073798
ENSE00001724267	71109795	71115382
ENSE00001739259	71076189	71076419
ENSE00001739855	71012985	71013202
ENSE00001764000	71050652	71050760
ENSE00001780658	71033931	71034036
ENSE00001784858	71026117	71026288
ENSE00003462422	70968198	70968243
ENSE00003484606	70946915	70947123
ENSE00003496295	70907459	70908003
ENSE00003497179	70962226	70962331
ENSE00003509110	71108604	71109046
ENSE00003511195	70988567	70988699
ENSE00003512674	71088330	71088430
ENSE00003522295	71057509	71057724
ENSE00003550211	71103395	71103669
ENSE00003573761	71009634	71009724
ENSE00003576409	71051883	71052012
ENSE00003591516	71109452	71109592
ENSE00003604189	71105235	71105440
ENSE00003610311	71089192	71089342
ENSE00003646539	70976942	70978648
ENSE00003653953	71055504	71055562
ENSE00003693573	71101990	71102220
ENSE00003693716	70969021	70969110

Expression profiles

Bgee: expression breadth ubiquitous, 275 present calls, max score 96.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.7458 / max 803.2397, expressed in 1783 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
140419	11.0599	1749
140421	7.3976	1570
140420	7.1872	1653
140422	3.0066	1048
140418	0.5478	258
140423	0.4933	186
140417	0.0533	18

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	96.99	gold quality
colonic epithelium	UBERON:0000397	95.42	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.47	gold quality
middle temporal gyrus	UBERON:0002771	94.30	gold quality
sural nerve	UBERON:0015488	94.30	gold quality
calcaneal tendon	UBERON:0003701	93.20	gold quality
parietal pleura	UBERON:0002400	93.09	gold quality
ventricular zone	UBERON:0003053	93.09	gold quality
blood	UBERON:0000178	92.93	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	92.44	gold quality
cortical plate	UBERON:0005343	91.66	gold quality
visceral pleura	UBERON:0002401	91.46	gold quality
pleura	UBERON:0000977	91.38	gold quality
germinal epithelium of ovary	UBERON:0001304	90.93	gold quality
endothelial cell	CL:0000115	90.82	gold quality
stromal cell of endometrium	CL:0002255	90.76	gold quality
ganglionic eminence	UBERON:0004023	90.67	gold quality
adrenal gland	UBERON:0002369	90.24	gold quality
biceps brachii	UBERON:0001507	89.68	gold quality
right adrenal gland	UBERON:0001233	89.66	gold quality
tendon	UBERON:0000043	89.63	gold quality
left adrenal gland	UBERON:0001234	89.62	gold quality
adrenal cortex	UBERON:0001235	89.61	gold quality
corpus callosum	UBERON:0002336	89.50	gold quality
left adrenal gland cortex	UBERON:0035825	89.48	gold quality
right adrenal gland cortex	UBERON:0035827	89.34	gold quality
right testis	UBERON:0004534	89.10	gold quality
left testis	UBERON:0004533	88.83	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.82	gold quality
pigmented layer of retina	UBERON:0001782	88.71	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.86
E-CURD-97	no	1071.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

274 targeting PCNX1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4775	99.98	75.00	6394

Literature-anchored findings (GeneRIF, showing 1)

• High PCNX expression is associated with lung cancer. (PMID:28789966)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pcnx1	ENSDARG00000011819
mus_musculus	Pcnx1	ENSMUSG00000021140
rattus_norvegicus	Pcnx1	ENSRNOG00000007459
drosophila_melanogaster	pcx	FBGN0003048
caenorhabditis_elegans	B0511.12	WBGENE00015237

Paralogs (3): PCNX4 (ENSG00000126773), PCNX2 (ENSG00000135749), PCNX3 (ENSG00000197136)

Protein

Protein identifiers

Pecanex-like protein 1 — Q96RV3 (reviewed: Q96RV3)

Alternative names: Pecanex homolog protein 1

All UniProt accessions (4): Q96RV3, H0YJ76, H0YJ91, H0YJZ0

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the pecanex family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q96RV3-1	1	yes
Q96RV3-2	2
Q96RV3-3	3
Q96RV3-4	4

RefSeq proteins (2): NP_001295089, NP_055797* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007735	Pecanex_C	Domain
IPR039797	Pecanex	Family

Pfam: PF05041

UniProt features (58 total): glycosylation site 16, compositionally biased region 15, transmembrane region 10, region of interest 7, splice variant 5, sequence variant 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96RV3-F1	57.38	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (16): 109, 215, 348, 394, 702, 852, 863, 1091, 1155, 1579, 1720, 1982, 2062, 2072, 2234, 2260

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 209 (showing top): LHX3_01, CAGCTG_AP4_Q5, STARK_HYPPOCAMPUS_22Q11_DELETION_UP, chr14q24, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, BIDUS_METASTASIS_UP, TGGAAA_NFAT_Q4_01, TAATTA_CHX10_01, PAX2_02, MULLIGHAN_MLL_SIGNATURE_1_UP, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP, EPPERT_HSC_R, WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_UP, GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN, GSE14415_NATURAL_TREG_VS_TCONV_UP

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	1

Protein interactions and networks

STRING

590 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PCNX1	STK31	Q9BXU1	443
PCNX1	CLEC14A	Q86T13	426
PCNX1	PSKH2	Q96QS6	422
PCNX1	ALLC	Q8N6M5	418
PCNX1	ZNF805	Q5CZA5	417
PCNX1	RAD51B	O15315	410
PCNX1	PREB	Q9HCU5	398
PCNX1	TEX11	Q8IYF3	395
PCNX1	KLHL28	Q9NXS3	392
PCNX1	PPP1CB	P37140	380
PCNX1	PYGL	P06737	372
PCNX1	SLC66A1LP	A1A4F0	370
PCNX1	TMEM117	Q9H0C3	358
PCNX1	ATXN7L1	Q9ULK2	339
PCNX1	GPHA2	Q96T91	333

IntAct

8 interactions, top by confidence:

A	B	Type	Score
TM2D3	TXNDC12	psi-mi:“MI:0914”(association)	0.640
PCNX1	NOP2	psi-mi:“MI:0915”(physical association)	0.400
M		psi-mi:“MI:0914”(association)	0.350
PCNX1	POTEF	psi-mi:“MI:0914”(association)	0.350
SLC16A10	STXBP3	psi-mi:“MI:0914”(association)	0.350
ETS1	PCNX1	psi-mi:“MI:0915”(physical association)	0.000
PCNX1	argS1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): PCNX (Affinity Capture-MS), PCNX (Proximity Label-MS), PCNX (Affinity Capture-MS), PCNX (Affinity Capture-RNA), PCNX (Proximity Label-MS), PCNX (Proximity Label-MS), PCNX (Affinity Capture-RNA), PCNX (Proximity Label-MS), ACTA2 (Affinity Capture-MS), POTEF (Affinity Capture-MS), PCNX (Affinity Capture-RNA), PCNX (Affinity Capture-RNA), PCNX (Affinity Capture-MS), PCNX (Affinity Capture-MS), PCNX (Affinity Capture-RNA)

ESM2 similar proteins: A0A1L8FZ84, A0A1S4GMU2, A0A2K1J5A5, A0A2K1JJ00, A0A2R6X6S3, A2AWL7, A2BIL8, A4IGV6, A9RNY0, B4GBA9, D3Z3C6, F4HYG2, F4J6F6, P10243, P24433, P46012, P46934, P51960, Q03237, Q05935, Q06616, Q06813, Q08729, Q0P4S0, Q290S5, Q5RD08, Q5T5U3, Q62417, Q69Z38, Q6DFB0, Q6DFV3, Q6P6I6, Q8IWI9, Q91018, Q949U2, Q96GY3, Q96RV3, Q9D722, Q9GSR1, Q9H792

Diamond homologs: A2RUW7, A6NKB5, E9PSU6, P18490, Q3UVY5, Q5DU28, Q5HZQ9, Q63HM2, Q8VI59, Q96RV3, Q98UF7, Q9H6A9, Q9QYC1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

78 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	24
Likely benign	9
Benign	11

Top pathogenic / likely-pathogenic (0)

SpliceAI

7632 predictions. Top by Δscore:

Variant	Effect	Δscore
14:70908000:CATGG:C	donor_loss	1.0000
14:70908004:G:GA	donor_loss	1.0000
14:70908005:T:A	donor_loss	1.0000
14:70946910:TAAAG:T	acceptor_loss	1.0000
14:70946911:A:AG	acceptor_gain	1.0000
14:70946911:AAAG:A	acceptor_gain	1.0000
14:70946912:A:G	acceptor_gain	1.0000
14:70946913:A:AG	acceptor_gain	1.0000
14:70946913:A:AT	acceptor_loss	1.0000
14:70946913:AG:A	acceptor_gain	1.0000
14:70946914:G:GG	acceptor_gain	1.0000
14:70946914:GG:G	acceptor_gain	1.0000
14:70947121:GAG:G	donor_gain	1.0000
14:70947123:GGTA:G	donor_loss	1.0000
14:70947124:G:C	donor_loss	1.0000
14:70947124:G:GG	donor_gain	1.0000
14:70947125:T:A	donor_loss	1.0000
14:70962221:CACA:C	acceptor_loss	1.0000
14:70962222:ACAGT:A	acceptor_gain	1.0000
14:70962223:C:G	acceptor_gain	1.0000
14:70962224:A:AG	acceptor_gain	1.0000
14:70962224:AGT:A	acceptor_gain	1.0000
14:70962225:G:GA	acceptor_gain	1.0000
14:70962225:GT:G	acceptor_gain	1.0000
14:70962225:GTG:G	acceptor_gain	1.0000
14:70962225:GTGAT:G	acceptor_gain	1.0000
14:70962332:G:GG	donor_gain	1.0000
14:70962333:T:A	donor_loss	1.0000
14:70968188:A:AG	acceptor_gain	1.0000
14:70968188:AC:A	acceptor_gain	1.0000

AlphaMissense

15350 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:71019070:G:A	G1020R	1.000
14:71019070:G:C	G1020R	1.000
14:71019124:T:C	C1038R	1.000
14:71019139:A:C	S1043R	1.000
14:71019141:C:A	S1043R	1.000
14:71019141:C:G	S1043R	1.000
14:71026141:A:C	S1070R	1.000
14:71026143:T:A	S1070R	1.000
14:71026143:T:G	S1070R	1.000
14:71050703:T:A	W1464R	1.000
14:71050703:T:C	W1464R	1.000
14:71050715:T:A	W1468R	1.000
14:71050715:T:C	W1468R	1.000
14:71055536:T:C	L1537S	1.000
14:71057538:T:C	F1556L	1.000
14:71057540:T:A	F1556L	1.000
14:71057540:T:G	F1556L	1.000
14:71057545:A:T	E1558V	1.000
14:71057563:T:C	L1564P	1.000
14:71057601:T:A	W1577R	1.000
14:71057601:T:C	W1577R	1.000
14:71057635:T:C	L1588P	1.000
14:71057650:T:C	L1593P	1.000
14:71057704:T:C	L1611P	1.000
14:71057709:G:A	G1613R	1.000
14:71057709:G:C	G1613R	1.000
14:71057710:G:A	G1613E	1.000
14:71057713:T:C	L1614P	1.000
14:71057718:T:C	F1616L	1.000
14:71057719:T:C	F1616S	1.000

dbSNP variants (sampled 300 via entrez): RS1000009196 (14:70965612 G>A), RS1000011274 (14:70943657 G>C), RS1000014897 (14:71090170 C>T), RS1000016893 (14:70913201 T>C), RS1000034952 (14:71068406 ATATATGTATT>A), RS1000042654 (14:70925863 T>C), RS1000053949 (14:71028349 C>A), RS1000093858 (14:70987324 G>C), RS1000110312 (14:70919658 A>C,G,T), RS1000141408 (14:70944221 T>G), RS1000159099 (14:71079711 A>C), RS1000210760 (14:71103993 C>G,T), RS1000214898 (14:70912808 G>A), RS1000217892 (14:71084792 G>A,T), RS1000219816 (14:70955090 G>A,C)

Disease associations

OMIM: gene MIM:617655 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST001658_2	Alzheimer’s disease (late onset)	6.000000e-06
GCST002579_26	Heschl’s gyrus morphology	2.000000e-06
GCST003094_6	Mitral valve prolapse	2.000000e-08
GCST003478_3	Hair greying	6.000000e-06
GCST004521_250	Autism spectrum disorder or schizophrenia	4.000000e-08
GCST007201_186	Schizophrenia	2.000000e-07
GCST007201_222	Schizophrenia	4.000000e-09
GCST007930_23	Medication use (agents acting on the renin-angiotensin system)	2.000000e-08
GCST008595_86	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	1.000000e-11
GCST010244_90	Triglyceride levels	3.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0009931	Agents acting on the renin-angiotensin system use measurement
EFO:0004337	intelligence
EFO:0004784	self reported educational attainment
EFO:0004530	triglyceride measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, increases expression, affects cotreatment	6
Benzo(a)pyrene	affects methylation, decreases methylation, increases mutagenesis	3
Nickel	increases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
methylmercuric chloride	decreases expression	1
bisphenol A	affects methylation	1
trichostatin A	increases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
jinfukang	decreases expression	1
(+)-JQ1 compound	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects methylation	1
Atrazine	increases expression	1
Caffeine	affects phosphorylation	1
Catechin	increases expression, affects cotreatment	1
Formaldehyde	decreases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects expression, increases abundance	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer